Galapagos raises $300M on the back of first PhIII filgotinib success; Incyte pushes into PhIII with topical Jakafi

Galapagos $GLPG wasn’t about to let the success of its first Phase III for filgotinib — handled by lead partner Gilead — go by without a quick raise. The biotech garnered $300 million from the sale of its stock.

Incyte $INCY says its Phase IIb study for a cream formulation of Jakafi (ruxolitinib) produced promising results for patients with atopic dermatitis. Researchers are now moving ahead with a Phase III registration program.

Principia BioPharma is now boosting the size of its proposed IPO. The South San Francisci-based biotech wants to sell 6.3 million shares at a price range of $15 to $17. 

VistaGen Therapeutics $VTGN issued a little more than $2 million in shares to Pheron Pharmaceuticals in exchange for rights to a drug for social anxiety disorder.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->